Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases - Top-Institutions - MDSpire

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

  • By

  • Xinhui Wang

  • Junyan Yu

  • May 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Heping Hospital
    Heping Hospital

    Heping, China

    Key Differentiators

    • Oncology

  • #2

    Changzhi Medical College
    Changzhi Medical College

    Changzhi, China

    Key Differentiators

    • Oncology

  • #3

    Peace Hospital
    Peace Hospital

    Peace, China

    Key Differentiators

    • Oncology

  • #4

    Chinese University of Hong Kong
    Chinese University of Hong Kong

    Hong Kong, Hong Kong

    Key Differentiators

    • Oncology

  • #5

    Vall d’Hebron University
    Vall d’Hebron University

    Barcelona, Spain

    Key Differentiators

    • Oncology

Original Source(s)

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

  • by Xinhui Wang, Junyan Yu

  • May 28, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen